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Objective. Tuberculosis control in foreign-born populations is a major public health concern for Australia, Canada, New Zealand,
United Kingdom, and the United States, large immigrant- and refugee-receiving countries that comprise the Immigration and
Refugee Health Working Group (IRHWG). Identifying and comparing immigration and distribution of foreign-born tuberculosis
cases are important for developing targeted and collaborative interventions.Methods. Data stratified by year and country of birth
from 2005 to 2009 were received from these five countries. Immigration totals, tuberculosis case totals, and multidrug-resistant
tuberculosis (MDRTB) case totals from source countries were analyzed and compared to reveal similarities and differences for each
member of the group. Results. Between 2005 and 2009, there were a combined 31,785,002 arrivals, 77,905 tuberculosis cases, and
888MDR TB cases notified at the federal level in the IRHWG countries. India, China, Vietnam, and the Philippines accounted for
41.4%of the total foreign-born tuberculosis cases and 42.7%of the foreign-bornMDR tuberculosis cases to IRHWG. Interpretation.
Collaborative efforts across a small number of countries have the potential to yield sizeable gains in tuberculosis control for these
large immigrant- and refugee-receiving countries.
1. Introduction
Tuberculosis is one of the world’s largest public health
challenges. Approximately one-third of the world’s popula-
tion is infected with tuberculosis (TB), and an estimated
1.5 million people die from the disease each year [1]. The
World Health Organization (WHO) established targets for
TB control by 2035 [2].These goals include targets for rates of
diagnosis and treatment completion rates for persons inside
a country [2]. However, migration is a factor that provides
challenges for meeting targets as well as opportunities for
control, particularly for countries with low incidence for TB
[3].
Worldwide, there are approximately 232 million inter-
national migrants, or 3.2% of the world’s population [4].
Although western, industrialized countries receive a large
percentage of international migrants, other parts of the world
also receive a large number of international migrants. Parts
of the world in which >10% of the population comprises
international migrants include the Gulf countries, Eastern
Europe, and even a few countries in Africa. Pertaining to TB,
many of the top source countries for international migrants
are also countries with a high burden of TB. For example,
the top source country for international migrants in 2013was
India, a country with the highest burden of TB [1]. Other top
countries for both international migrants and tuberculosis
cases include the Russian Federation, China, Bangladesh,
Pakistan, the Philippines, Afghanistan, and Indonesia.
Several of the world’s largest immigrant- and refugee-
receiving countries (Australia, Canada, New Zealand,
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the United States, and the United Kingdom) participate
in the Immigration and Refugee Health Working Group
(IRHWG), which aims to develop collaborative approaches
for immigration and refugee resettlements, including TB. A
majority of the TB cases in these countries are individuals
who were born abroad, and the threat of multidrug-resistant
(MDR) and extensively drug-resistant (XDR) TB is of signi-
ficant concern [5–9]. Each participating country currently
conducts TB screening overseas for immigrants (persons
applying for permanent residency) and refugees; all mem-
bers, except the United States, also perform TB screening
overseas for persons who will live in the receiving country >
6months, also known as long-term visitors [10–14].
To address modern TB threats, each IRHWG country is
in the process of improving TB prevention-control efforts,
especially as it relates to immigrant and refugee populations
with high burden of TB. To better identify the primary source
countries that contribute the largest migrating populations
and most TB cases to the group as a whole, we conducted an
analysis of arrivals and TB case diagnoses.
2. Methods
We analyzed data on TB cases and arrivals to Australia,
Canada, New Zealand, the United Kingdom, and the United
States. The arrival data from each IRHWG country include
long-term visitors, immigrant arrivals, and refugee arrivals;
the arrival data were obtained through the immigration
bureau for each country. The TB data are comprised of an
in-country diagnosis of foreign-born TB cases; the TB case
reporting came from theNational ReportingAgencies in each
IRHWG country.The authors acknowledge that the TB cases
in this analysis are not directly linked to the immigration data
presented.
All TB case data were stratified by year, birth country,
and type of TB (treatment-sensitive or MDR). For analysis
purposes, cumulative totals from 2005 to 2009 were utilized
to determine the total volume of immigrants and diagnosed
tuberculosis for each IRHWG country. Microsoft Excel and
JMP 9were used to construct tables in order to compare rela-
tionships among immigration totals, TB cases, and MDR TB
cases. The top 20 source countries for total immigrants, TB
cases, and MDR TB cases were determined using Microsoft
Excel. Bar graphs were constructed usingMicrosoftExcel and
R statistical software and tables made from Microsoft Excel
and JMP.
Because a goal of this analysis is to develop a perspective
as to which source countries are the largest ones for the
IRHWGmembers as a whole, irrespective of the numbers of
arrivals or cases, we calculated the average of the percentages
for each source country. This was calculated for arrivals,
foreign-born TB cases, and foreign-MDR TB cases. The cal-
culations in the bar graphs display the burden (immigration
volume, TB case volume, andMDR TB case volume) for each
member country, as well as the burden to the group as a
whole. For example, the average of each country’s proportion
of TB cases born in specific countries is shown in Figure 2 as
a bar graph. Each country’s proportion to the total TB burden
is also represented in the graph.
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Figure 1: Combined averages of arrivals, 2005–2009.
Ethical Considerations. Ethical approval and informed con-
sent were not required for this analysis.
3. Results
Between 2005 and 2009, there were 31,785,002 arrivals, 77,905
TB cases, and 888 MDR TB cases notified in these five
countries. The data in Figures 1–3 represent the averages of
each source country in respect to total arrivals, total TB cases,
and total MDR TB cases from 2005 to 2009. The top five
source countries for combined adjusted total arrivals (Fig-
ure 1) included India (11.5%), United Kingdom (8.6%), New
Zealand (8.6%), China (8.3%), and the Philippines (4.1%),
while the top five source countries for combined adjusted
total tuberculosis cases (Figure 2) were India (19.0%), the
Philippines (8.5%), China (8.3%), Vietnam (5.5%), and
Mexico (5.0%). Similarly, the top five source countries for
combined adjusted total MDR TB cases (Figure 3) were
India (15.6%), China (14.7%), Papua New Guinea (8.5%), the
Philippines (6.8%), and Vietnam (5.6%).
Data from the analysis reveal that India, China, Vietnam,
and the Philippines supplied the majority of diagnosed
TB counts. These four countries accounted for combined
adjusted 41.4% of the total foreign-born TB cases (Figure 2)
and 42.7% of the foreign-born MDR tuberculosis cases
(Figure 3). Of these, India was the leading source country for
arrivals (11.5% (Figure 1)), TB cases (19.0% (Figure 2)), and
MDR TB cases from 2005 to 2009 (15.6% (Figure 3)).
Primary source countries for total immigrant arrivals,
total TB cases, and total MDR TB cases varied for each of
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Figure 2: Combined averages of foreign-born TB cases, 2005–2009.
the five countries (Tables 1–3). Althoughmultiple similarities
were observed, the data reveal that four of the IRHWG coun-
tries have a specific source country/countries that contributes
a significant amount of TB cases without affecting the group
as a whole. Examples of specific source contributors include
PapuaNewGuinea (3.4%of foreign-born TB cases and 42.4%
of MDR TB cases) for Australia; Samoa (5.3% TB cases) for
New Zealand; Somalia (10.6% TB cases and 12.3% MDR TB
cases) and Pakistan (16.7% TB cases, 8.7% MDR TB cases)
for the United Kingdom; and Mexico (24.1% TB cases and
13.7% MDR TB cases) for the United States (Tables 1, 2, and
3). Canada received themajority of cases from the four largest
source countries (India, the Philippines, China, andVietnam)
but did not have a unique source country thatwas uncommon
to the other members. In this analysis, instead of grouping
countries by regions, we examined data for the individual
source country to understand their specific impact on our
immigration and TB programs.
4. Discussion
In this analysis, India, China, Vietnam, and the Philippines
contributed the largest proportion of foreign-born TB cases
toAustralia, Canada, NewZealand,UnitedKingdom, and the
United States as a whole during 2005–2009.The data used in
this analysis is a couple of years old, but the immigration and
TB trends are similar to the results of this analysis. The four
countries accounted for 41.4% of combined adjusted foreign-
born TB cases and 42.7% of the combined adjusted foreign-
bornMDR TB cases during this period of time. Each of these
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Figure 3: Combined averages of MDR TB cases, 2005–2009.
four countries is also included in the 2015WHO list of high-
burden countries with respect to TB [1].
However, these data also highlight the unique source
countries for each of these countries, which illustrate dif-
ferences in migration patterns. These unique situations may
reflect factors related to geography, such as Mexico as a
source country for the United States, or issues related to long-
standing historical ties, such as Pakistan for the United
Kingdom.
Although each country publishes immigration and TB
surveillance figures, and the importance of foreign-born TB
cases in industrialized countries has been described [15],
this is the first comparison of immigration and TB data
among large immigrant- and refugee-receiving countries to
our knowledge.
The results of this analysis alsomirror global comparisons
over time. Just as the global trends in international migra-
tion have increased over time, so the volumes of arrivals
have increased too during the study period. The growing
importance of Asian arrivals, in particular, is also reflected
in this analysis. In the United States, for example, the highest
proportion of immigrants to the United States transitioned
from Hispanics to Asians in 2009 [16].
The results also reflect global trends in TB, as many of the
top birth countries for TB cases are also WHO high-burden
countries. Although onlyfive receiving countries are included
in this analysis, the similarities (Figures 1–3) underscore the
need to develop collaborative strategies to address the burden
of TB in migrating populations [17].
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During the period of this analysis, an average of 6million
persons were admitted annually to the five participating
countries. Currently, approximately 2 million applicants for
migration status to these five countries are screened for TB
annually; the foreign-born TB cases which occur may or
may not be discovered through the screening process.These
examinations are performed by >2,000 panel physicians
worldwide. Panel physicians are medical doctors who have
agreements with each country to conduct the migrant med-
ical exam overseas. Each of the IRHWG countries require
overseas TB screening for all immigrants and refugees and
each except for the United States routinely requires screening
for long-term visitors. Moreover, all but the United Kingdom
have historically required this screening [18]; following a
successful pilot program in a limited number of countries,
the United Kingdom began a targeted overseas screening
program in 2012 for applicants fromhigh-incidence countries
[19]. Screening applicants for TB is very effective at prevent-
ing importation of active TB cases into the receiving countries
[20, 21].
Managing a modern overseas TB screening program for
migration and refugee resettlements results in development
of laboratory and treatment capacity. The TB screening
algorithms of IRHWG countries are similar in that they
either require (United States) or use (Australia, Canada,
New Zealand, and United Kingdom), where available, TB
cultures for those suspected of having active pulmonary TB,
drug susceptibility testing (DST) on positive isolates, and
treatment delivered as directly observed therapy (DOT) prior
to entry [10–14]. Since 2007, implementation of the US pro-
gram’s culture and DOT requirement has resulted in addi-
tional culture andDST laboratories as well as increased train-
ing for personnel involved with TB control [21, 22].
While each of these country’s efforts in managing TB
screening programs is invaluable for reducing importation
of TB, they should also be leveraged to assist with control
efforts within source countries. TB elimination in receiving
countries is difficult without addressing TB in foreign-
born populations [23]. For this reason, it is hoped that
improved linkages between panel physician activities and TB
control efforts within their countries would benefit the mig-
rants and others in their source populations. This analysis
helps demonstrate the fact that because panel physician vol-
umes are large in key source countries, these countries are
uniquely positioned to have their investments in the screen-
ing program also contribute to local control efforts [24]. And
this analysis helps determine for which countries that con-
tribution could be most needed. Additional benefits to
screening programs could possibly be achieved by having
panel physicians develop relationships with their TB control-
lers, share information on their experiences, share laboratory
capacity, and comanage TB cases where DOT capacity is
scarce.
The authors expected India to be a common source
country but were surprised that the average number of cases
wasmore than twice as high as that for the next two countries,
the Philippines and China. The participating countries have
collaborated closely with India, and this country was the
first country for implementation of the United Kingdom
screening program. However, the results of this analysis
highlight the importance of collaborations with India for
migrants, as well as for helping with overall TB control in
India, since it is the highest-burden country for TB world-
wide.
In many instances, TB treatment for those who travel to
the US may not occur until years after they have arrived.
While the data in this analysis shares source country of
the migrants, it does not automatically imply importation.
Individuals may acquire TB infection during travel or in the
United States upon arrival.
Although this analysis yields important findings regard-
ing migration and TB, there are some limitations. First, data
for this analysiswere only requested from 2005 to 2009, which
is a short period of time. If additional years were observed
for the analysis, additional trends for each country and the
group as a wholemight have been exposed. However, the data
from these five countries for subsequent years suggest similar
burdens of arrivals and diagnoses. Second, the analysis only
included data for five countries. While these are some of
the largest immigrant-receiving countries, additional future
analyses should include countries outside the group. The
analysis could have used data to separate the arrivals and TB
cases by visa types for each receiving country. This would
allow stratification of the arrivals and cases by populations
to see which had the highest TB rates within each country. It
is also important to note that the TB data were not stratified
by time since arrival. Thus, the potential exists that trends
among this subset may be slightly different. Finally, while this
analysis can be used to help participating countries in the
management of their screening programs by indicatingwhich
resources could be targeted, a cost-effectiveness review of
screening programs on potential collaborations was beyond
the scope of this analysis.
Australia, Canada, New Zealand, the United Kingdom,
and the United States are the largest immigrant- and refugee-
receiving countries in the world and are currently collabo-
rating on preventing importation of TB into each of their
countries. Joint efforts in a small number of high-burden
countries can help prevent importation of TB cases and also
contribute to control efforts within source countries.
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